Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ko Yamamoto

Showing results (51-60 of 96) with videos related to

Pageof 10
Sort By:
The American Journal of Cardiology|December 6, 2020
Periprocedural Stroke After Coronary Revascularization (from the CREDO-Kyoto PCI/CABG Registry Cohort-3)Ko Yamamoto, Masahiro Natsuaki, Takeshi Morimoto, et al.
The American Journal of Cardiology|January 17, 2021
Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Versus Without Chronic Kidney DiseaseKo Yamamoto, Masahiro Natsuaki, Takeshi Morimoto, et al.
The American Journal of Cardiology|July 7, 2024
Post-procedural Anticoagulation With Unfractionated Heparin in Acute Coronary Syndrome: Insight from the STOPDAPT-3 TrialHirotoshi Watanabe, Masahiro Natsuaki, Takeshi Morimoto, et al.
Journal of the American College of Cardiology|October 25, 2023
Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary InterventionHirotoshi Watanabe, Takeshi Morimoto, Masahiro Natsuaki, et al.
European Heart Journal|August 31, 2024
Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trialHirotoshi Watanabe, Masahiro Natsuaki, Takeshi Morimoto, et al.
Circulation. Cardiovascular Interventions|May 18, 2021
Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 TrialKo Yamamoto, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Plos One|November 17, 2021
Differences in mortality and causes of death between STEMI and NSTEMI in the early and late phases after acute myocardial infarctionYasuaki Takeji, Hiroki Shiomi, Takeshi Morimoto, et al.
The American Journal of Cardiology|October 28, 2021
Ischemic and Bleeding Events After First Major Bleeding Event in Patients Undergoing Coronary Stent ImplantationKo Yamamoto, Masahiro Natsuaki, Takeshi Morimoto, et al.
Circulation. Cardiovascular Interventions|March 18, 2026
Clopidogrel Versus Aspirin Monotherapy Beyond 1 Year After PCI: The Final 5-Year Results of the STOPDAPT-2 ACS and STOPDAPT-2 Total CohortHirotoshi Watanabe, Takeshi Morimoto, Masahiro Natsuaki, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|April 28, 2021
Effects of Acute Coronary Syndrome and Stable Coronary Artery Disease on Bleeding and Ischemic Risk After Percutaneous Coronary InterventionMasahiro Natsuaki, Takeshi Morimoto, Hiroki Shiomi, et al.
Pageof 10

Showing results (51-60 of 96) with videos related to

Sort By:
Pageof 10
The American Journal of Cardiology|December 6, 2020
Periprocedural Stroke After Coronary Revascularization (from the CREDO-Kyoto PCI/CABG Registry Cohort-3)Ko Yamamoto, Masahiro Natsuaki, Takeshi Morimoto, et al.
The American Journal of Cardiology|January 17, 2021
Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Versus Without Chronic Kidney DiseaseKo Yamamoto, Masahiro Natsuaki, Takeshi Morimoto, et al.
The American Journal of Cardiology|July 7, 2024
Post-procedural Anticoagulation With Unfractionated Heparin in Acute Coronary Syndrome: Insight from the STOPDAPT-3 TrialHirotoshi Watanabe, Masahiro Natsuaki, Takeshi Morimoto, et al.
Journal of the American College of Cardiology|October 25, 2023
Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary InterventionHirotoshi Watanabe, Takeshi Morimoto, Masahiro Natsuaki, et al.
European Heart Journal|August 31, 2024
Aspirin vs. clopidogrel monotherapy after percutaneous coronary intervention: 1-year follow-up of the STOPDAPT-3 trialHirotoshi Watanabe, Masahiro Natsuaki, Takeshi Morimoto, et al.
Circulation. Cardiovascular Interventions|May 18, 2021
Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients Who Underwent Complex Percutaneous Coronary Intervention: Insight From the STOPDAPT-2 TrialKo Yamamoto, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Plos One|November 17, 2021
Differences in mortality and causes of death between STEMI and NSTEMI in the early and late phases after acute myocardial infarctionYasuaki Takeji, Hiroki Shiomi, Takeshi Morimoto, et al.
The American Journal of Cardiology|October 28, 2021
Ischemic and Bleeding Events After First Major Bleeding Event in Patients Undergoing Coronary Stent ImplantationKo Yamamoto, Masahiro Natsuaki, Takeshi Morimoto, et al.
Circulation. Cardiovascular Interventions|March 18, 2026
Clopidogrel Versus Aspirin Monotherapy Beyond 1 Year After PCI: The Final 5-Year Results of the STOPDAPT-2 ACS and STOPDAPT-2 Total CohortHirotoshi Watanabe, Takeshi Morimoto, Masahiro Natsuaki, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|April 28, 2021
Effects of Acute Coronary Syndrome and Stable Coronary Artery Disease on Bleeding and Ischemic Risk After Percutaneous Coronary InterventionMasahiro Natsuaki, Takeshi Morimoto, Hiroki Shiomi, et al.
Pageof 10